RT Journal Article
T1 Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients.
A1 Gutierrez-Bautista, Juan Francisco
A1 Martinez-Chamorro, Alba
A1 Rodriguez-Nicolas, Antonio
A1 Rosales-Castillo, Antonio
A1 Jimenez, Pilar
A1 Anderson, Per
A1 Lopez-Ruz, Miguel Angel
A1 Lopez-Nevot, Miguel Angel
A1 Ruiz-Cabello, Francisco
K1 MICA
K1 MICA STR polymorphisms
K1 NK cells
K1 SARS-CoV-2
K1 innate immunity
AB The SARS-CoV-2 disease presents different phenotypes of severity. Comorbidities, age, and being overweight are well established risk factors for severe disease. However, innate immunity plays a key role in the early control of viral infections and may condition the gravity of COVID-19. Natural Killer (NK) cells are part of innate immunity and are important in the control of virus infection by killing infected cells and participating in the development of adaptive immunity. Therefore, we studied the short tandem repeat (STR) transmembrane polymorphisms of the major histocompatibility complex class I chain-related A (MICA), an NKG2D ligand that induces activation of NK cells, among other cells. We compared the alleles and genotypes of MICA in COVID-19 patients versus healthy controls and analyzed their relation to disease severity. Our results indicate that the MICA*A9 allele is related to infection as well as to symptomatic disease but not to severe disease. The MICA*A9 allele may be a risk factor for SARS-CoV-2 infection and symptomatic disease.
PB MDPI AG
YR 2022
FD 2022-06-22
LK http://hdl.handle.net/10668/21168
UL http://hdl.handle.net/10668/21168
LA en
NO Gutiérrez-Bautista JF, Martinez-Chamorro A, Rodriguez-Nicolas A, Rosales-Castillo A, Jiménez P, Anderson P, et al. Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients. Int J Mol Sci. 2022 Jun 23;23(13):6979.
NO This work was supported by grants from the Instituto de Salud Carlos III cofinanced byFEDER funds (European Union) (PI 16/00752) and (B-CTS-410-UGR-20) and Junta de Andalucía inSpain (Group CTS-143). P.A. is supported by the Consejería de Salud, Junta de Andalucía through thecontract “Nicolás Monardes” [C-0013-2018]. Palex Medical S.A. has covered the costs of publication
DS RISalud
RD Apr 18, 2025